SCHEMBL25787729

SCHEMBL25787729

CC(F)(I)c1ccc(Nc2ccccc2-c2nnn(CCOc3ccccc3)n2)cc1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 3/20 0.42
▸ TSHR P16473 1/20 0.42
▸ LMNA P02545 3/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ ABCG2 Q9UNQ0 7/20 0.40
▸ SMN1; SMN2 Q16637 4/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ MAPT P10636 5/20 0.39
▸ MEN1 O00255 3/20 0.37
▸ KMT2A Q03164 3/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ ABCB1 P08183 1/20 0.37
▸ DDX3X O00571 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ JAK2 O60674 1/20 0.36
▸ JAK3 P52333 1/20 0.36
▸ PTK2 Q05397 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20551929 0.91 USP2 (0.48) USP2TSHRLMNAALDH1A1ABCG2
SCHEMBL25787722 0.89 ABCG2 (0.42) USP2TSHRLMNAALDH1A1ABCG2
SCHEMBL25787726 0.89 USP2 (0.43) USP2TSHRLMNAALDH1A1ABCG2
SCHEMBL25787764 0.86 LMNA (0.42) USP2TSHRLMNAABCG2SMN1; SMN2
SCHEMBL21749260 0.85 ABCG2 (0.42) USP2TSHRLMNAABCG2SMN1; SMN2
SCHEMBL25787803 0.83 USP2 (0.46) USP2TSHRLMNAALDH1A1ABCG2
SCHEMBL21749248 0.82 USP2 (0.48) USP2TSHRLMNAALDH1A1ABCG2
SCHEMBL20552459 0.81 ABCG2 (0.47) TSHRLMNAALDH1A1ABCG2SMN1; SMN2
SCHEMBL21749240 0.79 ABCG2 (0.43) USP2LMNAABCG2SMN1; SMN2MAPT
SCHEMBL20552934 0.79 ABCG2 (0.42) TSHRLMNAALDH1A1ABCG2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 USP2 2622/4885TSHR 2680/4885LMNA 2451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback